Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 1F

CHEMBL1805 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1805
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 1F as ChEMBL target CHEMBL1805, mapped to UniProt P30939. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 1F
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1805
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30939
5-hydroxytryptamine receptor 1F
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 1F matters

As of 2026-09-13

5-hydroxytryptamine receptor 1F is reviewed as 5-hydroxytryptamine receptor 1F (UniProt P30939); 5-hydroxytryptamine receptor 1F shows approved-linked disease relevance led by migraine disorder. 1 more disease program remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 176 compounds, and 62 assays, with lead potency reaching pChEMBL 9.5.

Disease context
migraine disorder

5-hydroxytryptamine receptor 1F shows approved-linked disease relevance led by migraine disorder. 1 more disease program remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, LASMIDITAN.

Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, LASMIDITAN, LASMIDITAN SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 176 compounds, and 62 assays for this target. The dominant activity type is KI. CHEMBL4851044 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL4851044 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 1F matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30939, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why migraine disorder is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

176
Total Compounds
62
Total Assays
4
Approved Drugs
IC50: 17.0, KI: 151.0, EC50: 27.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4851044
 9.5 IC50 —
No preferred name
CHEMBL128636
 8.8 Ki —
No preferred name
CHEMBL101690
 8.8 Ki —
No preferred name
CHEMBL361303
 8.7 Ki —
No preferred name
CHEMBL3039520
 8.7 Ki Approved

Approved Drugs

Structure Compound First Approval
LASMIDITAN
CHEMBL3039520
 2020
SUMATRIPTAN
CHEMBL128
 1992
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1805